Mr. Paul Duffy reports

AI/ML SUBSIDIARY NEURALCLOUD APPOINTS CARDIAC MONITORING VETERANS DALE AND NICHOLAS DUBOIS TO LEAD CLINICAL AND OVERREAD OPERATIONS

AI-ML Innovations Inc.'s wholly owned subsidiary, NeuralCloud Solutions Inc., has appointed Dale DuBois, ASN, as clinical operations lead, and Nicholas DuBois, BS, CCT, as vice-president of overread operations. The appointments bring deep, hands-on cardiac monitoring leadership to NeuralCloud as the company builds the clinical governance and operational foundation to support its neural-network ECG (electrocardiogram) signal-processing technology as it advances through the regulatory pathway.

Purpose-built operating leadership for NeuralCloud's next phase

NeuralCloud has reached an important stage in its evolution as it is currently advancing its neural-network ECG signal-processing technology through development, validation and regulatory review. Ms. DuBois and Mr. DuBois join at exactly this inflection point, bringing the clinical governance and operating expertise needed to build the standards, workflows and team that will support the technology as it moves toward potential future commercialization.

Together, Ms. DuBois and Mr. DuBois bring more than 50 years of combined experience inside the cardiac monitoring industry. As co-founders of Global TeleMonitoring LLC, they built, trained and led the kind of clinical governance and overread operation that NeuralCloud's technology is being developed to support, giving them a rare operator's perspective on the workflows the company is building for.

Ms. DuBois, clinical operations lead

Ms. DuBois brings more than 30 years of experience in cardiac monitoring operations, medical device clinical leadership, and regulatory-facing validation, following a decade in bedside critical-care nursing earlier in her career. Most recently in executive leadership at Peerbridge Health, she established enterprise clinical governance, quality standards and regulatory-aligned workflows supporting the delivery of more than 10,000 cardiac monitoring reports. She has led clinical validation activities across 10 clinical sites for FDA (U.S. Food and Drug Administration) clearance, including Mount Sinai (New York), Northwell Health, Henry Ford Hospital, Hackensack Meridian Health and Cone Memorial Hospital, and built and trained an overread team of more than 30 cardiac technicians. Beginning her career as a registered nurse in coronary and intensive care, Ms. DuBois carries a patient-first clinical instinct into every governance decision. She is GCP (good clinical practice) certified, was a CCRN-certified (critical-care registered nurse) registered nurse and is the founder of the Space Coast Chapter of the American Association of Critical-Care Nurses.

As clinical operations lead, Ms. DuBois will oversee NeuralCloud's clinical governance, quality standards and regulatory-aligned workflows and serve as a senior clinical adviser as the company prepares its technology for potential future commercialization.

Mr. DuBois, vice-president of overread operations

Mr. DuBois brings more than 20 years of experience leading ECG overread services, algorithm validation, and scalable ECG analysis and interpretation workflows. As co-founder of Global TeleMonitoring and, most recently, director of overread services at Peerbridge Health, he built, trained and managed overread teams of more than 25 cardiac technicians and designed workflows optimized for throughput, cost-efficiency and quality control. He has led the validation and integration of multiple third -party ECG algorithms and workstations and partnered with research and product teams to refine algorithm performance and usability. He holds a bachelor of science from the University of North Florida and is a certified cardiac technician (CCT) and is GCP certified.

As vice-president of overread operations, Mr. DuBois will lead the design of NeuralCloud's overread workflows, quality control processes, and pilot and validation programs, building the operational capability the company will rely on as its technology advances toward commercialization.

Leadership commentary

"Dale and Nick are exactly the voices this market trusts," said Paul Duffy, executive chairman and chief executive officer of AI-ML. "Cardiac monitoring is a small, trust-based profession, and credibility comes from people who have run the floor themselves. Between them, Dale and Nick have built and led the kind of clinical operation our technology is being designed to support. Bringing that lived experience inside NeuralCloud strengthens our clinical and operational foundation as we advance through regulatory review."

"I have spent my career building overread operations where quality and efficiency have to co-exist," said Mr. DuBois, vice-president of overread operations of NeuralCloud. "What drew me to NeuralCloud is the chance to build that operational discipline from the ground up, with the rigour this field demands, as the company advances its technology through development and regulatory review."

"In more than three decades inside cardiac monitoring, I have learned that throughput means nothing without clinical governance and patient safety underneath it," said Ms. DuBois, clinical operations lead of NeuralCloud. "What drew me to NeuralCloud is a team that puts that discipline first. I look forward to establishing the clinical standards and regulatory-aligned workflows that this work demands."

Strengthening NeuralCloud's operating platform

The appointments reflect NeuralCloud's strategy of pairing AI (artificial intelligence) innovation with deep operational expertise. Ms. DuBois and Mr. DuBois will work in close co-ordination with Erik Suokas, chief operating officer, and alongside the company's medical advisory board, with Ms. DuBois and Mr. DuBois engaged in clinical governance and operational standards that will underpin the company's technology and validation programs. Their addition strengthens NeuralCloud's clinical and operational readiness while maintaining the regulatory discipline this field requires.

About AI-ML Innovations Inc.

AI-ML Innovations is a technology company developing artificial intelligence and neural-network solutions for digital health. Its proprietary technology applies advanced signal processing and deep learning to enhance the quality of complex biometric and cardiac signal data.

AI-ML's shares trade on the Canadian Securities Exchange (symbol: AIML), the OTCQB Venture Market (symbol: AIMLF) and the Frankfurt Stock Exchange (symbol: 42FB).

We seek Safe Harbor.